FDAnews Drug Daily Bulletin

The FDA and HHS have done all they can administratively to curb drug shortages and now need additional help from Congress, HHS Secretary Kathleen Sebelius told lawmakers Feb. 15. The health chief told the Senate Finance Committee the FDA would strongly benefit from pending bills, S. 296 and H.R. 2245, that would mandate six months notification by drugmakers discontinuing, interrupting or adjusting manufacture of a drug known to be in short supply.
Generic Line